Johnson & Johnson’s 82.5% implied probability of beating Q3 2026 earnings reflects sustained momentum from its innovative medicines segment, including strong sales of Tremfya and other key products that drove a Q2 beat with $25.3 billion in reported revenue and prompted raised full-year guidance. Analysts currently project adjusted EPS of $2.96, a 5.7% increase year-over-year, supported by 5–6% operational growth trends and favorable margin dynamics. Traders are pricing in continuity of this performance ahead of the October 13 earnings release, though any MedTech softness or regulatory headwinds could narrow the margin of outperformance.